The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer - PubMed (original) (raw)
doi: 10.1111/his.12398. Epub 2014 Apr 16.
Darragh G McArt, Gareth Irwin, Charlotte S Wilhelm-Benartzi, Tong F Lioe, Elena Sebastian, Stephen McQuaid, Peter W Hamilton, Jacqueline A James, Paul B Mullan, Mark A Catherwood, D Paul Harkin, Manuel Salto-Tellez
Affiliations
- PMID: 24612173
- DOI: 10.1111/his.12398
The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer
David P Boyle et al. Histopathology. 2014 Sep.
Abstract
Aims: The utility of p53 as a prognostic assay has been elusive. The aims of this study were to describe a novel, reproducible scoring system and assess the relationship between differential p53 immunohistochemistry (IHC) expression patterns, TP53 mutation status and patient outcomes in breast cancer.
Methods and results: Tissue microarrays were used to study p53 IHC expression patterns: expression was defined as extreme positive (EP), extreme negative (EN), and non-extreme (NE; intermediate patterns). Overall survival (OS) was used to define patient outcome. A representative subgroup (n = 30) showing the various p53 immunophenotypes was analysed for TP53 hotspot mutation status (exons 4-9). Extreme expression of any type occurred in 176 of 288 (61%) cases. As compared with NE expression, EP expression was significantly associated (P = 0.039) with poorer OS. In addition, as compared with NE expression, EN expression was associated (P = 0.059) with poorer OS. Combining cases showing either EP or EN expression better predicted OS than either pattern alone (P = 0.028). This combination immunophenotype was significant in univariate but not multivariate analysis. In subgroup analysis, six substitution exon mutations were detected, all corresponding to extreme IHC phenotypes. Five missense mutations corresponded to EP staining, and the nonsense mutation corresponded to EN staining. No mutations were detected in the NE group.
Conclusions: Patients with extreme p53 IHC expression have a worse OS than those with NE expression. Accounting for EN as well as EP expression improves the prognostic impact. Extreme expression positively correlates with nodal stage and histological grade, and negatively with hormone receptor status. Extreme expression may relate to specific mutational status.
Keywords: breast cancer; immunohistochemistry; mutation; p53 protein; prognosis.
© 2014 John Wiley & Sons Ltd.
Similar articles
- Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P, Nenutil R, Muller P, Hrstka R, Appleyard MV, Murray K, Jordan LB, Purdie CA, Quinlan P, Thompson AM, Vojtesek B, Coates PJ. Bouchalova P, et al. J Pathol. 2014 Jul;233(3):238-46. doi: 10.1002/path.4356. Epub 2014 May 21. J Pathol. 2014. PMID: 24687952 - Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.
Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M. Fernández-Cuesta L, et al. Breast Cancer Res. 2012 May 2;14(3):R70. doi: 10.1186/bcr3179. Breast Cancer Res. 2012. PMID: 22551440 Free PMC article. Clinical Trial. - Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G, Ishida T, Furuta A, Takahashi S, Watanabe M, Nakata H, Kato S, Ishioka C, Ohuchi N. Watanabe G, et al. Am J Surg Pathol. 2015 Aug;39(8):1026-34. doi: 10.1097/PAS.0000000000000386. Am J Surg Pathol. 2015. PMID: 26171916 - Triple-negative breast cancer: current state of the art.
Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S. Rastelli F, et al. Tumori. 2010 Nov-Dec;96(6):875-88. Tumori. 2010. PMID: 21388048 Review. - Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.
Li X, Chen X, Wen L, Wang Y, Chen B, Xue Y, Guo L, Liao N. Li X, et al. Thorac Cancer. 2020 Jul;11(7):1861-1868. doi: 10.1111/1759-7714.13467. Epub 2020 May 15. Thorac Cancer. 2020. PMID: 32412177 Free PMC article.
Cited by
- Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations.
Armbruster H, Schotte T, Götting I, Overkamp M, Granai M, Volmer LL, Bahlinger V, Matovina S, Koch A, Dannehl D, Engler T, Hartkopf AD, Brucker SY, Bonzheim I, Fend F, Staebler A, Montes-Mojarro I. Armbruster H, et al. Virchows Arch. 2024 Aug 27. doi: 10.1007/s00428-024-03897-3. Online ahead of print. Virchows Arch. 2024. PMID: 39191994 - NKX3.1 Expression and Molecular Characterization of Secretory Myoepithelial Carcinoma (SMCA): Advancing the Case for a Salivary Mucous Acinar Phenotype.
Patel S, Wald AI, Bastaki JM, Chiosea SI, Singhi AD, Seethala RR. Patel S, et al. Head Neck Pathol. 2023 Jun;17(2):467-478. doi: 10.1007/s12105-023-01524-2. Epub 2023 Feb 6. Head Neck Pathol. 2023. PMID: 36746884 Free PMC article. - Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy.
Hamada S, Kano S, Murai J, Suzuki T, Tsushima N, Mizumachi T, Suzuki M, Takashima T, Taniyama D, Sakamoto N, Fujioka Y, Ohba Y, Homma A. Hamada S, et al. Front Oncol. 2023 Jan 19;12:978875. doi: 10.3389/fonc.2022.978875. eCollection 2022. Front Oncol. 2023. PMID: 36741698 Free PMC article. - The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwara M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T, Nagao T. Saigusa N, et al. Front Oncol. 2022 Feb 3;11:779882. doi: 10.3389/fonc.2021.779882. eCollection 2021. Front Oncol. 2022. PMID: 35186711 Free PMC article. - Orthogonal MET analysis in a population-representative stage II-III colon cancer cohort: prognostic and potential therapeutic implications.
Craig SG, Mende S, Humphries MP, Bingham V, Viratham Pulsawatdi A, Loughrey MB, Coleman HG, McQuaid S, Wilson RH, Van Schaeybroeck S, James JA, Salto-Tellez M. Craig SG, et al. Mol Oncol. 2021 Dec;15(12):3317-3328. doi: 10.1002/1878-0261.13089. Epub 2021 Nov 1. Mol Oncol. 2021. PMID: 34428346 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous